SP-2509 has been suggested to slow down tumor growth by inhibiting LSD1 [19, 29], and its potential as a therapeutic agent has been explored in a phase I clinical trial including patients with Ewing sarcoma [30]. This evidence concerns the gene KDM1A and Ewing sarcoma.